MAPS Public Benefit Corporation (PBC) has announced a $100m Series A alongside a name change to Lykos Therapeutics. MAPS PBC was founded in 2014 as a separate but wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 by Rick Doblin. MAPS PBC was to be the non-profit’s pharmaceutical arm, tasked with bringing MDMA-assisted…

Source

Previous articlePsychedelic Research Bulletin: December 2023
Next articlePα+ Psychedelic Patent Analysis (November 2023)